Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International (NYSE:BAX) announces its 2021 Annual Meeting will be virtual due to COVID-19 safety concerns. Scheduled for May 4, 2021, at 9 a.m. CT, the meeting will begin online access at 8:30 a.m. Shareholders can vote in advance or electronically during the meeting. Questions for management can be submitted via proxyvote.com until May 3, 2021, or live during the event. A shareholder list will be available online. Baxter continues to support critical healthcare innovations worldwide.
Baxter International Inc. (NYSE:BAX) has announced a conference call scheduled for April 29, 2021, at 7:30 a.m. Central Time to discuss its first-quarter 2021 financial results. Participants can pre-register via a provided link to receive call information. The call will also be accessible through Baxter's website.
Baxter, a leader in medical products, serves millions of patients globally with a diverse portfolio aimed at critical care and innovation in healthcare solutions.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its AK 98 dialysis machine, which aims to provide a portable and user-friendly option for administering hemodialysis (HD) treatments. The AK 98 features encrypted connectivity, auto alert resolution, and an intuitive interface to streamline workflows in chronic and hospital care settings. This platform has been established in over 90 countries and will be available in the U.S. soon. The system is designed to enhance treatment efficiency and patient management.
Baxter International will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, with CFO Jay Saccaro presenting at 10:40 a.m. ET. The presentation will be accessible via a live webcast at www.baxter.com, and available for replay until September 13, 2021. Baxter is a leader in medical products, providing critical care, nutrition, and renal products globally for over 85 years.
Baxter International and Moderna have entered an agreement for Baxter's BioPharma Solutions to manufacture and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. The manufacturing will occur in Bloomington, Indiana, utilizing Baxter's 20 years of experience in vaccine production. This partnership aims to enhance Moderna's manufacturing capacity in the U.S., allowing for the expedited rollout of the vaccine to meet public health needs.
Baxter International (NYSE:BAX) has appointed Dr. David S. Wilkes to its board of directors, enhancing its leadership with his extensive medical and biotech experience. Dr. Wilkes, dean of the University of Virginia School of Medicine, will serve on Baxter’s Quality, Compliance and Technology Committee. Albert P.L. Stroucken is named lead independent director, succeeding Thomas T. Stallkamp, who remains on the board. The changes reflect Baxter's commitment to diversify its board while maintaining experienced oversight. The board now consists of 13 members.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.245 per share, payable on April 1, 2021, to shareholders on record as of February 26, 2021. This sets an annual indicative dividend rate at $0.98 per share. Baxter, with over 85 years of experience, focuses on critical care, nutrition, and surgical products, impacting millions globally. The company’s forward-looking statements suggest that future dividend payouts may vary based on several risk factors.
Baxter International reported fourth-quarter sales of $3.2 billion, a 5% year-over-year increase, despite a flat U.S. market. International sales rose 8%, driven by Acute Therapies demand during COVID-19. Fourth-quarter net income was $168 million or $0.33 per share, influenced by special items totaling $244 million. For 2020, sales reached $11.7 billion, up 3%, with net income of $1.1 billion. The company expects 2021 sales growth of 7-8% and adjusted earnings per share of $3.35 to $3.43. Baxter remains committed to shareholder value and innovation amidst ongoing challenges.
Baxter International (NYSE:BAX) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:40 a.m. Eastern Time. Jay Saccaro, the company’s CFO, is scheduled to speak. A live webcast of the presentation will be available on www.baxter.com and can be replayed until May 25, 2021. Baxter has a legacy of over 85 years in transforming healthcare through innovations in critical care, nutrition, renal, and surgical products, serving patients in over 100 countries.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
